In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program

Diagnostic Microbiology and Infectious Disease

Volumn 81, Issue 4, 2015, Pages 283-289

  Flamm, Robert K ^a   Mendes, Rodrigo E ^a   Hogan, Patricia A ^b   Ross, James E ^a   Farrell, David J ^a,c   Jones, Ronald N ^a,d  

^a JMI LABORATORIES   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

LEADER; Linezolid; Oxazolidinones

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIFAMOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; RIBOSOME PROTEIN; RIBOSOME PROTEIN L22; RIBOSOME PROTEIN L3; RIBOSOME PROTEIN L4; RNA 23S; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; CFR GENE; CLINICAL ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DISK DIFFUSION; DRUG ACTIVITY; DRUG DETERMINATION; DRUG SURVEILLANCE PROGRAM; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EPSILOMETER TEST; FEMALE; GENE MUTATION; HUMAN; IN VITRO STUDY; MALE; METHICILLIN RESISTANT COAGULASE NEGATIVE STAPHYLOCOCCUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE COAGULASE NEGATIVE STAPHYLOCOCCUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SANGUINIS; UNITED STATES; YOUNG ADULT; DRUG EFFECTS; ENTEROCOCCUS; GRAM POSITIVE INFECTION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCUS; STREPTOCOCCUS; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LINEZOLID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCUS; STREPTOCOCCUS; UNITED STATES; YOUNG ADULT;

EID: 84925168505     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.12.009     Document Type: Article

References (30)

1. Arias C.A., Vallejo M., Reyes J., Panesso D., Moreno J., Castaneda E., et al. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J Clin Microbiol 2008, 46:892-896.
2. Burleson B.S., Ritchie D.J., Micek S.T., Dunne W.M. Enterococcus faecalis resistant to linezolid: case series and review of the literature. Pharmacotherapy 2004, 24:1225-1231.
3. Clinical and Laboratory Standards Institute (CLSI) M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2012, CLSI, Wayne, PA. ninth ed.
4. Clinical and Laboratory Standards Institute (CLSI) M02-A11. Performance standards for antimicrobial disk susceptibility tests; approved standard 2012, CLSI, Wayne, PA. eleventh ed.
5. Clinical and Laboratory Standards Institute (CLSI) M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement 2014, CLSI, Wayne, PA.
6. Diaz L., Kiratisin P., Mendes R., Panesso D., Singh K.V., Arias C.A. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 2012, 56:3917-3922.
7. Draghi D.C., Sheehan D.J., Hogan P., Sahm D.F. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2005, 49:5024-5032.
8. Draghi D.C., Sheehan D.F., Hogan P., Sahm D.F. Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting. Diagn Microbiol Infect Dis 2006, 55:129-133.
9. Farrell D.J., Mendes R.E., Ross J.E., Jones R.N. Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 2009, 65:392-403.
10. Farrell D.J., Mendes R.E., Ross J.E., Sader H.S., Jones R.N. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from the United States (56 medical centers). Antimicrob Agents Chemother 2011, 55:3684-3690.
11. Flamm R.K., Farrell D.J., Mendes R.E., Ross J.E., Sader H.S., Jones R.N. LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn Microbiol Infect Dis 2012, 74:54-61.
12. Flamm R.K., Mendes R.E., Ross J.E., Sader H.S., Jones R.N. Linezolid surveillance results for the United States: LEADER Surveillance Program 2011. Antimicrob Agents Chemother 2013, 57:1077-1081.
13. Flamm R.K., Mendes R.E., Ross J.E., Sader H.S., Jones R.N. An international activity and spectrum analysis of linezolid: ZAAPS program results for 2011. Diagn Microbiol Infect Dis 2013, 76:206-213.
14. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001, 357:1179.
15. Jones R.N., Fritsche T.R., Sader H.S., Ross J.E. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Diagn Microbiol Infect Dis 2007, 59:309-317.
16. Jones R.N., Ross J.E., Castanheira M., Mendes R.E. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2008, 62:416-426.
17. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., Vester B. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 2006, 50:2500-2505.
18. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 2008, 52:2244-2246.
19. Mendes R.E., Deshpande L.M., Farrell D.J., Spanu T., Fadda G., Jones R.N. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother 2010, 65:2329-2335.
20. Mendes R.E., Deshpande L.M., Kim J., Myers D., Ross J.E., Jones R.N. Streptococcus sanguinis displaying a cross resistance phenotype to several ribosomal RNA targeting agents, including linezolid. 52nd ICAAC, September 9-12, 2012. Abstr. C1-1343. San Francisco, CA, USA 2012.
21. Mendes R.E., Deshpande L.M., Bonilla H.F., Schwarz S., Huband M.D., Jones R.N., et al. Dissemination of a pSCFS3-like cfr-carrying plasmid in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates recovered from hospitals in Ohio. Antimicrob Agents Chemother 2013, 57:2923-2928.
22. Mendes R.E., Deshpande L.M., Kim J., Myers D.S., Ross J.E., Jones R.N. Streptococcus sanguinis displaying a cross resistance phenotype to several ribosomal RNA targeting agents. J Clin Microbiol 2013, 51:2728-2731.
23. Mendes R.E., Deshpande L.M., Jones R.N. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat 2014, 17:1-12.
24. Mendes R.E., Flamm R.K., Hogan P.A., Ross J.E., Jones R.N. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States. Antimicrob Agents Chemother 2014, 58:1243-1247.
25. Mendes R.E., Hogan P.A., Streit J.M., Jones R.N., Flamm R.K. Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: Report of linezolid activity over nine years (2004-2012). J Antimicrob Chemother 2014, 69:1582-1588.
26. Toh S.M., Xiong L., Arias C.A., Villegas M.V., Lolans K., Quinn J., et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007, 64:1506-1514.
27. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358:207-208.
28. Wilson P., Andrews J.A., Charlesworth R., Walesby R., Singer M., Farrell D.J., et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003, 51:186-188.
29. Zhanel G.G., Adam H.J., Baxter M.R., Fuller J., Nichol K.A., Denisuik A.J., et al. Antimicrobial susceptibility of 22,746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother 2013, 68(Suppl. 1):i7-i22.
30. Zurenko G.E., Yagi B.H., Schaadt R.D., Allison J.W., Kilburn J.O., Glickman S.E., et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996, 40:839-845.